ADRN-12/LEADS (Longitudinal Endotyping of Atopic Dermatitis Through Transcriptomic Skin Analysis)


Trial Objective

Eczema (atopic dermatitis) is typically classified as mild, moderate or severe. In this trial, researchers are studying gene expression for the varying severity levels of eczema in order to guide new and improved treatments strategies and more personalized treatments. Skin samples from participants will be collected using a specialized, noninvasive dermatologic skin tape. People with and without eczema are needed for this trial.


Active Clinical Trials Currently Recruiting

Who Can Participate

Adults ages 18 and older and kids ages 6 to 17 with and without eczema.

Age: 6-65    Gender: Any Gender

Estimated Time Commitment

7-8 clinic visits over five to six months.

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Trish Taylor

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

National Institutes of Health

Principal Investigators

Request More Information

By completing this form, you agree to learn more about this study and see if you qualify.

 I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: